Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $520000.0.

  • Guided Therapeutics' Operating Expenses fell 730.84% to $520000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 1096.15%. This contributed to the annual value of $2.1 million for FY2024, which is 3959.35% down from last year.
  • Per Guided Therapeutics' latest filing, its Operating Expenses stood at $520000.0 for Q3 2025, which was down 730.84% from $842000.0 recorded in Q2 2025.
  • Guided Therapeutics' 5-year Operating Expenses high stood at $1.5 million for Q2 2023, and its period low was $363000.0 during Q1 2024.
  • For the 5-year period, Guided Therapeutics' Operating Expenses averaged around $682578.9, with its median value being $563000.0 (2021).
  • In the last 5 years, Guided Therapeutics' Operating Expenses skyrocketed by 24008.26% in 2021 and then crashed by 5759.35% in 2024.
  • Quarter analysis of 5 years shows Guided Therapeutics' Operating Expenses stood at $476000.0 in 2021, then soared by 82.56% to $869000.0 in 2022, then tumbled by 42.35% to $501000.0 in 2023, then grew by 6.19% to $532000.0 in 2024, then dropped by 2.26% to $520000.0 in 2025.
  • Its Operating Expenses stands at $520000.0 for Q3 2025, versus $842000.0 for Q2 2025 and $414000.0 for Q1 2025.